$1.43
1.40% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US15117K1034
Symbol
CLLS
Sector
Industry

Cellectis SA Sponsored ADR Stock price

$1.43
-0.08 5.32% 1M
-0.47 24.75% 6M
-0.37 20.57% YTD
-1.05 42.35% 1Y
-14.35 90.94% 5Y
-39.25 96.49% 10Y
-37.87 96.36% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
+0.02 1.40%
ISIN
US15117K1034
Symbol
CLLS
Sector
Industry

Key metrics

Market capitalization $106.84m
P/E (TTM) P/E ratio negative
P/S ratio (TTM) P/S ratio 1.35
Revenue growth (TTM) Revenue growth 357.32%
Revenue (TTM) Revenue $79.30m
EBIT (operating result TTM) EBIT $-84.50m
EPS (TTM) EPS $-0.77
P/E forward negative
P/S forward 2.63
Short interest 0.42%
Show more

Is Cellectis SA Sponsored ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,836 stocks worldwide.

Cellectis SA Sponsored ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Cellectis SA Sponsored ADR forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Cellectis SA Sponsored ADR forecast:

Buy
71%
Hold
29%

Financial data from Cellectis SA Sponsored ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
79 79
357% 357%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 15 15
21% 21%
18%
- Research and Development Expense 65 65
6% 6%
82%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -85 -85
39% 39%
-107%
Net Profit -78 -78
31% 31%
-98%

In millions USD.

Don't miss a Thing! We will send you all news about Cellectis SA Sponsored ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cellectis SA Sponsored ADR Stock News

Neutral
GlobeNewsWire
22 days ago
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that it will hold its annual general meeting on June 26, 2025 at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris...
Positive
Seeking Alpha
28 days ago
Cellectis SA's pipeline consists of allogeneic CAR T-cell therapies that have the potential to make meaningful dents in heme malignancies. The financial picture remains strong, bolstered further by a partnership with AstraZeneca. Promised data readouts in late 2025 represent important potential catalysts.
Neutral
GlobeNewsWire
about one month ago
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the first quarter 2025, ending March 31, 2025, and provided a business update.
More Cellectis SA Sponsored ADR News

Company Profile

Cellectis SA is a biopharmaceutical company, which engages in the research and development of genome engineering technology. The company operates through the following segments: Therapeutics and Plants. The Therapeutics segment is focused on the development of products in the field of immune-oncology and of novel products outside immuno-oncology to treat other human diseases. The Plants segment focuses on applying its gene-editing technologies to develop new generation plant products in the field of agricultural biotechnology through its own efforts or through alliances with other companies in the agricultural market. Its therapeutic products are still in the preclinical stage which is developed for various kinds of tumors. Cellectis was founded by David J. Sourdive and André Choulika on February 20, 1999 and is headquartered in Paris, France.

Head office France
CEO André Choulika
Employees 219
Founded 1999
Website www.cellectis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today